In recognition of #AmericanHeartMonth, Lexicon is committed to raising awareness of heart disease. Hypertrophic cardiomyopathy is a genetic heart disorder impacting the left ventricle and limiting blood flow. #HCM impacts approximately 1.1 million people in the U.S.

Today, we honor #WomenInScience and recognize several of our esteemed clinical investigators - Dr. Sharlene Day, Dr. Carolyn Ho and Dr. Rodica Pop-Busui. Their pioneering work in cardiometabolic research is vital to advancing patient care.

We’ll be attending the 2025 BIO CEO & Investor Conference on February 10-11. Our CEO, Mike Exton, will present on our innovative drug pipeline, including pilavapadin (LX9211) and our R&D approach. Here’s to a great event with engaging discussions – hope to see many of you there!

#ICYMI - We hosted a webcast on the diabetic peripheral neuropathic pain (DPNP) landscape with experts Rodica Pop-Busui, MD, PhD and Steve Edelman, MD. Catch the replay for insights into the patient experience and treatment needs:

Team Lexicon will be at Booth #1 at the American Diabetes Association Clinical Update Conference in Orlando, FL this weekend discussing the latest in diabetes care. Hope to see many of you there!

Don’t forget to join our virtual webcast for a discussion about transforming the paradigm for treating diabetic peripheral neuropathic pain (DPNP). Sign up:

Next week, Lexicon leaders will be joining experts in a virtual webcast about treatment of diabetic peripheral neuropathic pain (DPNP). Learn more:

An article was published in the Journal of Diabetes Investigation, highlighting the potential role of our investigational treatment in diabetic peripheral neuropathy pain (DPNP). Learn more:

Lexicon is gearing up for a busy December with participation in three upcoming healthcare investor conferences. Tune into our presentations or find the replays on our Events page: #LexiconNews

Lexicon is pleased to announce we’ve completed enrollment of our Phase 2b PROGRESS study evaluating our investigational therapy for diabetic peripheral neuropathic pain (DPNP). Learn more: #LexiconNews

We'll be at the Jefferies 2024 London Healthcare Conference on Wednesday, Nov. 20. Find our webcast details here: #LexiconNews

Thank you @BreakthroughT1D for hosting the 51st Greater New York Metro Promise Gala last week and for all your work in advocating for the #Diabetes community. It was an inspiring night!

In honor of #WorldDiabetesDay, we were at the @BreakthroughT1D Greater New York Promise Metro Gala last night to show our support for people with #Diabetes and to champion research breakthroughs for this community.

#AHA24 Scientific Sessions are around the corner! Visit our oral presentations, moderated posters and poster presentations on Nov. 16 & 17 to learn more about the latest data from our SGLT1/2 inhibitor program for patients with #HeartFailure. Read more:

It’s #WorldDiabetesDay! Thrilled to have joined the #Diabetes community at @BreakthroughT1D walks around the country. Thank you to everyone who participated and showed their support.

Lexicon’s 2024 Q3 financial results are now available. See our full earnings press release here: #LexiconNews

We're excited to attend the @BreakthroughT1D Greater New York Metro Gala on November 14 in recognition of #WorldDiabetesDay! Check out the highlights from last year and learn more about this inspiring event:

We’re at Obesity Week 2024 to present data from two #Obesity and #WeightLoss studies. We look forward to discussing the latest in obesity research and treatments with the scientific community. Learn more: #LexiconNews #OW2024

We’re excited to share results of the Phase 3 SCORED clinical trial, highlighting benefits for patients with diabetic kidney disease at #ASN24. Read more: #KidneyWk #LexiconNews

We’ve completed screening and look forward to completing enrollment in our Phase 2b PROGRESS study for LX9211, targeting diabetic peripheral neuropathic pain (DPNP). Learn more: #LexiconNews